Form 4: Unity Biotechnology CFO Lynne Sullivan Granted Stock Options

Lynne Marie Sullivan, CFO of Unity Biotechnology, was granted stock options for 150,000 shares on January 22, 2025.

Summary

• Lynne Marie Sullivan, the CFO & Head of Corporate Development at Unity Biotechnology, Inc. (UBX), was granted stock options.
• The transaction occurred on January 22, 2025.
• Sullivan received options for 150,000 shares of common stock at an exercise price of $2.09 per share.
• The options vest over time, with one-third vesting on December 31, 2025, and the remainder vesting in 24 equal monthly installments thereafter, until December 31, 2027, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own. It's a standard practice for executive compensation.

Positives

• The granting of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates